Pitcairn Co. Has $387,000 Stock Holdings in Genmab A/S (NASDAQ:GMAB)

Pitcairn Co. lifted its holdings in shares of Genmab A/S (NASDAQ:GMAB) by 70.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 18,541 shares of the company’s stock after purchasing an additional 7,640 shares during the quarter. Pitcairn Co.’s holdings in Genmab A/S were worth $387,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of GMAB. EverSource Wealth Advisors LLC increased its position in Genmab A/S by 295.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock worth $26,000 after buying an additional 939 shares during the last quarter. Lindbrook Capital LLC increased its holdings in shares of Genmab A/S by 105.4% during the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock valued at $39,000 after acquiring an additional 950 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Genmab A/S by 96.6% in the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock valued at $45,000 after acquiring an additional 1,051 shares in the last quarter. Cromwell Holdings LLC lifted its holdings in Genmab A/S by 656.8% in the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company’s stock worth $60,000 after purchasing an additional 2,496 shares during the last quarter. Finally, R Squared Ltd bought a new stake in Genmab A/S during the fourth quarter worth approximately $93,000. Institutional investors own 7.07% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Leerink Partners raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price target on the stock in a research report on Thursday, February 13th. HC Wainwright reissued a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a research report on Thursday, January 23rd. William Blair raised Genmab A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 11th. Truist Financial cut their price objective on Genmab A/S from $50.00 to $45.00 and set a “buy” rating for the company in a research report on Tuesday, March 11th. Finally, Sanford C. Bernstein lowered Genmab A/S from a “market perform” rating to an “underperform” rating in a report on Tuesday, April 1st. One investment analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $41.33.

Genmab A/S Trading Down 4.4 %

Shares of NASDAQ:GMAB opened at $18.39 on Friday. The firm has a market capitalization of $12.17 billion, a PE ratio of 10.57, a PEG ratio of 2.65 and a beta of 1.07. Genmab A/S has a 1-year low of $18.30 and a 1-year high of $30.41. The business’s 50 day moving average is $20.67 and its 200-day moving average is $21.61.

Genmab A/S (NASDAQ:GMAB) last issued its earnings results on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. On average, sell-side analysts predict that Genmab A/S will post 1.45 EPS for the current year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.